Fotios Plakogiannis
Founder at Transdermal Research Pharm Laboratories LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Pedro Lichtinger | M | 70 |
ChemioCare, Inc.
 ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY.
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 7 years |
| Douglas Janzen | M | 56 |
Transdermal Research Pharm Laboratories LLC
| 11 years |
| Nitin Kaushal | M | 58 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017.
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | 6 years |
| Eric Baum | M | 48 |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY.
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 6 years |
| Rodoula Plakogiannis | M | - |
Transdermal Research Pharm Laboratories LLC
Long Island University
| 22 years |
| Roy F. Waldron | M | 61 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 5 years |
| Rapp Alyssa | F | 45 | - | |
| Moses Dodo | M | 65 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 2 years |
| Mohamad Hussein | M | - |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017.
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| George Hornig | M | 69 | - | |
| Ann Fehr | F | 55 | 8 years | |
| Bai Chun Xiao | M | 76 |
Long Island University
| 26 years |
| James Oliver | M | 68 | - | |
| Scott Kahn | M | 62 | - | |
| Roy Waldon | M | - |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| John MacCarthy | M | 64 | - | |
| Roman Rogol | M | - |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Cidnee Vaykovich | F | - |
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | - |
| Asher Chanan-Khan | M | 55 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | - |
| Kenneth Anderson | M | 72 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 4 years |
| Christopher Clark | M | 54 | 10 years | |
| John Regazzi | M | 76 |
Long Island University
| 19 years |
| Andrew Rensink | M | 68 | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Flowerday | M | 51 | 8 years | |
| Da Long Jeng | M | 55 |
Long Island University
| 6 years |
| Hamed Shahbazi | M | 49 | - | |
| Edward L. Donnelly | M | 68 |
Long Island University
| 6 years |
| Christopher Tyrkko | M | - |
Long Island University
| 5 years |
| Michael Winters | M | - |
Long Island University
| 4 years |
| Damien King | M | - | - | |
| Howard Lorber | M | 75 |
Long Island University
| 12 years |
| Scott Feigeles | M | - |
Long Island University
| 4 years |
| Uzonwa A. Adogu | F | - |
Long Island University
| 2 years |
| Steven D. Baderian | M | - |
Long Island University
| 3 years |
| John Tomeo | M | - |
Long Island University
| 2 years |
| John Matthews | M | 62 |
Long Island University
| 4 years |
| John Raymont | M | - |
Long Island University
| 2 years |
| Roger Ardan | M | - |
Long Island University
| 2 years |
| Peter Messineo | M | 63 |
Long Island University
| 2 years |
| Xavier Smith | M | - |
Long Island University
| 4 years |
| Steven L. Relis | M | 61 |
Long Island University
| 4 years |
| Bob Pearsall | M | - |
Long Island University
| 4 years |
| Sid Kopperl | M | 77 |
Long Island University
| 4 years |
| Frank Patrick Marzano | M | - |
Long Island University
| 1 years |
| Mark Weinreb | M | 71 |
Long Island University
| 1 years |
| Paul Rouse | M | 65 |
Long Island University
| 4 years |
| Stephen Moore | M | 59 |
Long Island University
| 2 years |
| Bjorn Almroth | M | 53 |
Long Island University
| 4 years |
| Jiann Shyang Wey | M | 61 |
Long Island University
| 2 years |
| Mikkel Tolnaes | M | - |
Long Island University
| 3 years |
| Kishore Gangangari | M | - |
Long Island University
| 3 years |
| Kwane Thomas | M | - |
Long Island University
| 4 years |
| Gregory Vilkin | M | - |
Long Island University
| 4 years |
| Phil Skolnick | M | 77 |
Long Island University
| 5 years |
| Stephen J. Suspenski | M | - |
Long Island University
| 1 years |
| Marina Massingham | F | - | 3 years | |
| Stuart Scheinman | M | 58 |
Long Island University
| 4 years |
| Brumello Carlo Fabrizio Pianca | M | 65 |
Long Island University
| 2 years |
| Yik Nam Ip | M | 44 |
Long Island University
| 2 years |
| Ian Ball | M | - | 5 years | |
| Alexander Goumeniouk | M | - | - | |
| Charlie Perperidis | M | - | - | |
| Robert E. Spielman | M | - |
Long Island University
| 4 years |
| James Flynn | M | - |
Long Island University
| 2 years |
| Sean Peter Rooney | M | 53 |
Long Island University
| 4 years |
| Sasha S. Masri | M | 43 |
Long Island University
| 4 years |
| Bruce Lipnick | M | - |
Long Island University
| 4 years |
| Clifford R. Kitey | M | - |
Long Island University
| 4 years |
| Mark Alan Boyar | M | - |
Long Island University
| 4 years |
| Mike Emmerman | M | - |
Long Island University
| 2 years |
| Sal Naro | M | - |
Long Island University
| 4 years |
| Colin B. Bier | M | 77 |
Long Island University
| 1 years |
| Malcolm F. McNeill | M | - |
Long Island University
| 1 years |
| Robert Edward Bies | M | 66 |
Long Island University
| 4 years |
| Adele Ruger | F | - |
Long Island University
| 4 years |
| Clarence A. Davis | M | 81 |
Long Island University
| 4 years |
| Gifford A. Dieterle | M | 91 |
Long Island University
| 22 years |
| George W. Kromer | M | 83 |
Long Island University
| 1 years |
| Edward J. Rasmussen | M | 75 |
Long Island University
| 2 years |
| Thomas Axmacher | M | 65 |
Long Island University
| 2 years |
| Thomas Melendez | M | - |
Long Island University
| 4 years |
| Donald Alan McAfee | M | 82 | - | |
| Gary D. Tureski | M | - |
Long Island University
| 4 years |
| John W. Krey | M | - |
Long Island University
| 3 years |
| Edward James King | M | - |
Long Island University
| 2 years |
| David Earl Kaleoikaika Cooper | M | - |
Long Island University
| 1 years |
| Frank Arnone | M | 77 |
Long Island University
| 4 years |
| Kamal Dua | M | - |
Long Island University
| 2 years |
| Stan Robinson | M | - |
Long Island University
| 4 years |
| Michael D. Grosso | M | - |
Long Island University
| 3 years |
| Patrick Lauria | M | - |
Long Island University
| 2 years |
| John Barry | M | 65 |
Long Island University
| 4 years |
| Michael Stoler | M | - |
Long Island University
| 4 years |
| Jian H. Wang | M | - |
Long Island University
| 4 years |
| Ami Dotan | M | - |
Long Island University
| 2 years |
| Christina Yip | F | - | 2 years | |
| Scott Guy Seaman | M | - |
Long Island University
| 4 years |
| Peter Wilson | M | 56 | - | |
| Andrew C. Lunetta | M | - |
Long Island University
| 4 years |
| Brendan Sihksnel | M | - |
Long Island University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 82 | 82.00% |
| Canada | 14 | 14.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Fotios Plakogiannis
- Personal Network
